These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Investigation of asymptomatic visceral leishmaniasis cases using western blot in an endemic area in Turkey. Sakru N; Korkmaz M; Ozbel Y; Ertabaklar H; Sengul M; Toz SO New Microbiol; 2007 Jan; 30(1):13-8. PubMed ID: 17319595 [TBL] [Abstract][Full Text] [Related]
27. Comparison of serological methods (ELISA, DAT and IFA) for diagnosis of visceral leishmaniasis utilizing an endemic strain. Mikaeili F; Fakhar M; Sarkari B; Motazedian MH; Hatam G Iran J Immunol; 2007 Jun; 4(2):116-21. PubMed ID: 17652852 [TBL] [Abstract][Full Text] [Related]
28. CD26/dipeptidyl peptidase IV: a comparative study of healthy persons and kidney transplant recipients before and early after transplantation. Leicht S; Shipkova M; Klett C; Gert H; Altrock E; Wilhelm J; Bolley R; Wollmeyer J; Ender A; Luz B; Olbricht C; Wieland E Clin Biochem; 2013 Oct; 46(15):1383-8. PubMed ID: 23608353 [TBL] [Abstract][Full Text] [Related]
29. Age-dependent changes of serum soluble CD30 concentration in children. Chrul S; Polakowska E Pediatr Transplant; 2011 Aug; 15(5):515-8. PubMed ID: 21672104 [TBL] [Abstract][Full Text] [Related]
30. Soluble CD30 serum levels in atopic dermatitis and bronchial asthma and its relationship with disease severity in pediatric age. Heshmat NM; El-Hadidi ES Pediatr Allergy Immunol; 2006 Jun; 17(4):297-303. PubMed ID: 16771784 [TBL] [Abstract][Full Text] [Related]
31. Leishmania infantum-induced primary and challenge infections in rhesus monkeys (Macaca mulatta): a primate model for visceral leishmaniasis. Porrozzi R; Pereira MS; Teva A; Volpini AC; Pinto MA; Marchevsky RS; Barbosa AA; Grimaldi G Trans R Soc Trop Med Hyg; 2006 Oct; 100(10):926-37. PubMed ID: 16455120 [TBL] [Abstract][Full Text] [Related]
33. [Investigation of anti-Leishmania seroprevalence by different serologic assays in children inhabiting in the northwestern part of Turkey]. Doğan N; Bör O; Dinleyici EC; Töz SO; Ozbel Y Mikrobiyol Bul; 2008 Jan; 42(1):103-11. PubMed ID: 18444567 [TBL] [Abstract][Full Text] [Related]
34. A variant in the promoter of MBL2 is associated with protection against visceral leishmaniasis in Morocco. Hamdi S; Ejghal R; Idrissi M; Ezzikouri S; Hida M; Soong L; Amarouch H; Lemrani M Infect Genet Evol; 2013 Jan; 13():162-7. PubMed ID: 22995279 [TBL] [Abstract][Full Text] [Related]
35. CD30 antigen: not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response. Pellegrini P; Berghella AM; Contasta I; Adorno D Transpl Immunol; 2003; 12(1):49-61. PubMed ID: 14551032 [TBL] [Abstract][Full Text] [Related]
36. Do the initial serum level changes of sCD26 have ability to predict successful treatment with IFN-α among naïve chronic hepatitis B patients? Alavi-Moghaddam M; Alavian SM; Aalaei-Andabili SH; Eslami-Far A Vaccine; 2011 Nov; 29(48):9093-7. PubMed ID: 21893143 [TBL] [Abstract][Full Text] [Related]
37. CD30 antigen and multiple sclerosis: CD30, an important costimulatory molecule and marker of a regulatory subpopulation of dendritic cells, is involved in the maintenance of the physiological balance between TH1/TH2 immune responses and tolerance. The role of IFNbeta-1a in the treatment of multiple sclerosis. Pellegrini P; Totaro R; Contasta I; Berghella AM; Carolei A; Adorno D Neuroimmunomodulation; 2005; 12(4):220-34. PubMed ID: 15990453 [TBL] [Abstract][Full Text] [Related]
38. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response. Ramos I; Alonso A; Marcen JM; Peris A; Castillo JA; Colmenares M; Larraga V Vaccine; 2008 Jan; 26(3):333-44. PubMed ID: 18093705 [TBL] [Abstract][Full Text] [Related]
40. An evaluation of serum soluble CD30 levels and serum CD26 (DPPIV) enzyme activity as markers of type 2 and type 1 cytokines in HIV patients receiving highly active antiretroviral therapy. Keane NM; Price P; Lee S; Stone SF; French MA Clin Exp Immunol; 2001 Oct; 126(1):111-6. PubMed ID: 11678906 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]